Uso de IECA/ARA II no reduce la progresión de la enfermedad renal crónica 3-4 en la nefropatía diabética

Contenido principal del artículo

Edwin Castillo Velarde
Diego Delgado Cabrera
Miguel Angello Tinoco Begazo
Christoper Alarcón-Ruiz

Detalles del artículo

Cómo citar
1.
Castillo Velarde E, Delgado Cabrera D, Tinoco Begazo MA, Alarcón-Ruiz C. Uso de IECA/ARA II no reduce la progresión de la enfermedad renal crónica 3-4 en la nefropatía diabética. Rev Nefrol Dial Traspl. [Internet]. 15 de septiembre de 2020 [citado 27 de octubre de 2021];40(2):185-8. Disponible en: http://www.revistarenal.org.ar/index.php/rndt/article/view/530
Sección
Carta al Comité Editor

Citas

1) Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-62. doi: 10.1056/NEJM199311113292004.

2) Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359-64. doi: 10.1016/S0140-6736(98)10363-X.

3) Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol. 2012;7(6):989-1002. doi: 10.2215/CJN.07800811.

4) Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9. doi: 10.1056/NEJMoa011161.

5) Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60. doi 10.1056/NEJMoa011303.

6) Abboud H, Henrich W. Stage IV chronic kidney disease. N Engl J Med. 2010;362(20):1942; author reply 1943. doi: 10.1056/NEJMc1002223.

7) Hebert L. Optimizing ACE-inhibitor therapy for chronic kidney disease. N Engl J Med. 2006;354(2):189-91. doi: 10.1056/NEJMe058295.

8) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253-9.

9) Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010;25(12):3977-82. doi: 10.1093/ndt/gfp511.

10) Suissa S, Hutchinson T, Brophy JM. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006;69(5):913-9. doi. 10.1038/sj.ki.5000159.

11) Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-35. doi: 10.1053/j.ajkd.2014.01.416.

12) Hou FF, Zhang X, Zhang GH. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131-40. doi: 10.1056/NEJMoa053107.

13) Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001;38(6):E28-32. doi: 10.1161/hy1101.099502.

14) ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. doi: 10.1056/NEJMoa0801317.